{"id":"palmitoylethanolamide-sold-as-levagen","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL417675","moleculeType":"Small molecule","molecularWeight":"299.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PEA is an endocannabinoid-like compound that acts as a ligand for PPAR-α, leading to downregulation of mast cell degranulation and microglial activation. This reduces the release of pro-inflammatory mediators and neuropeptides involved in pain signaling, thereby providing analgesic and anti-inflammatory effects without direct cannabinoid receptor activation.","oneSentence":"Palmitoylethanolamide is an endogenous fatty acid amide that modulates pain and inflammation by activating peroxisome proliferator-activated receptor alpha (PPAR-α) and reducing neuroinflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:25.476Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuropathic pain"},{"name":"Chronic pain conditions"}]},"trialDetails":[{"nctId":"NCT05003453","phase":"PHASE2, PHASE3","title":"The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema","status":"COMPLETED","sponsor":"RDC Clinical Pty Ltd","startDate":"2021-11-29","conditions":"Eczema, Atopic","enrollment":72},{"nctId":"NCT05046522","phase":"PHASE3","title":"A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.","status":"COMPLETED","sponsor":"RDC Clinical Pty Ltd","startDate":"2021-09-01","conditions":"Migraine","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Levagen+"],"phase":"phase_3","status":"active","brandName":"Palmitoylethanolamide sold as Levagen +","genericName":"Palmitoylethanolamide sold as Levagen +","companyName":"RDC Clinical Pty Ltd","companyId":"rdc-clinical-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Palmitoylethanolamide is an endogenous fatty acid amide that modulates pain and inflammation by activating peroxisome proliferator-activated receptor alpha (PPAR-α) and reducing neuroinflammation. Used for Neuropathic pain, Chronic pain conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}